Home
About
Share This
Set as HomepageTradjenta
HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not ...
1 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use TRADJENTA safely and effectively. See full prescribing information for TRADJENTA.
U.S. FACT SHEET
TJ91461PR U.S. FACT SHEET TRADJENTA overview • TRADJENTA (pronounced TRAD-gen-ta) is approved in the U.S. to be used along with diet and exercise to lower blood sugar in adults with type 2 diabetes.
Prior Authorization Criteria for the Dipeptidyl Peptidase ...
Prior Authorization Criteria for the Dipeptidyl Peptidase Inhibitors (DPP4s) – Januvia, Janumet, Onglyza, Kombiglyze XR, Tradjenta. Background
Linagliptin in Type 2 Diabetes Media Fact Sheet
June 2010 1. Linagliptin: An overview 2. DPP-4 Inhibitors: A novel class of treatment in type 2 diabetes 3. Linagliptin: Profile and clinical trials programme _____ 1.
PATIENT EDUCATION HANDOUTS High Blood Pressure (Hypertension)
bl PATIENT EDUCATION HANDOUTS High Blood Pressure (Hypertension) Overview What is high blood pressure? Blood pressure is a measure of how hard the blood pushes against the walls of your arteries as it moves through your body.
CENTER FOR DRUG EVALUATION AND RESEARCH
NDA 201280 CMC Director Review Tradjenta* (Linagliptin) Tablets * This proposed name has not yet been finalized in negotiations between the Agency and Boehringer Ingelheim.
CRT-USPC-MK0431-T-9984405
9984405 HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use JANUVIA safely and effectively. See full prescribing information for JANUVIA.
What is in this leaflet
Amaryl ® (am-a(r)-RILL) glimepiride (glim-epi-RIDE) Consumer Medicine Information (CMI) What is in this leaflet This leaflet answers some common questions about Amaryl.
201280Orig1s000 CROSS DISCIPLINE TEAM LEADER REVIEW
Labeling The proprietary name Tradjenta is under review at the time of this writing. Labeling negotiations are ongoing. The product will carry a PPI, ...
